ErVaccine

ErVaccine Technologies is a clinical-stage French biotechnology company specializing in the development of next-generation cancer vaccines and T-cell therapies. The company leverages its proprietary Meta-HERV platform to identify and target shared antigens derived from Human Endogenous Retroviruses (HERVs), which are specifically expressed in tumor cells but not in healthy tissues. Their lead candidate, EVX-01, is a therapeutic vaccine designed to treat patients with advanced solid tumors. By targeting these dark matter regions of the genome, ErVaccine aims to overcome the limitations of traditional neoantigen-based approaches. The company's pipeline also includes TCR-T cell therapies and vaccines for specific indications like triple-negative breast cancer. ErVaccine is a spin-off from the Centre Léon Bérard and the Cancer Research Center of Lyon, benefiting from strong academic and clinical ties.